Table 5. EBNA2-VDR joint binding inside RA and SLE associated regions.
| ANALYSIS DESCRIPTION | enrichment (O/E) | p-value | case/control analysis 1 | p-value |
|---|---|---|---|---|
| 'EBNA2 and VDR joint occupancy track' inside 'RA non MHC regions' | 1.29 | 0.3443 | 6.841 | 0.0193 |
| 'EBNA2 and VDR joint occupancy track' inside 'RA regions including MHC' | 1.232 | 0.3426 | 6.679 | 0.0213 |
| 'EBNA2 and VDR joint occupancy track' inside 'SLE non MHC regions' | 3.329 | 0.3849 | 2.366 | 0.1805 |
| 'EBNA2 and VDR joint occupancy track' inside 'SLE regions including MHC' | 3.195 | 0.3776 | 2.321 | 0.1772 |
Overlap results for EBNA2-VDR joint occupancy track within RA and SLE regions, and excess enrichment of case-control analysis
O/E: factor of observed vs expected overlap; 1: EED for EBNA2-VDR joint occupancy track on MS regions (case) relatively to control regions (RA, SLE).
EBNA2 = Epstein-Barr nuclear antigen 2; VDR = Vitamin D receptor; RA = Rheumatoid arthritis; SLE = Systemic lupus erythematosus; MHC = Major histocompatibility complex.